IND submission is a critical milestone in mAb development — but analytical methods established at this stage must ultimately support validation, tech transfer, and evolving regulatory expectations. Among these, residual host cell DNA quantitation assays play a central role in monitoring residual impurity levels, supporting process performance, and may help reduce downstream risks. This webinar...
We are very excited to invite you to our BVS, in collaboration with JLL Biotech Community Innovation Night at 115 Munson! Mark your calendars for a great opportunity to connect with industry leaders, explore innovative products, and mingle with fellow professionals in the biotech community. We are inviting all research scientists from the institutes, biotech...
Explore how advanced nanoparticle engineering is transforming formulation across both small and large molecule modalities. Dr. Chris Worrall highlights how Nanoform’s technologies enable higher drug‑loading oral tablets, ultra‑high‑concentration biologic formulations for SubQ delivery, and new possibilities for pulmonary administration. Through real case studies, you’ll see how nanoforming can reduce pill burden, unlock patient‑friendly alternatives to...
In this session, leading cell therapy CDMOs will break down how they support programs across development—from early process work through GMP manufacturing, scale-up, and commercial readiness—and where different approaches can reduce downstream risk or introduce it. This is a focused look at who does what, and where they fit—so you can evaluate partners with greater...
Increasing titers isn’t the only way to maximize process efficiency. Whether you’re optimizing an existing process or developing the next generation of biologics, we can help you identify the levers that matter most. Join us for an interactive discussion on the process decisions, tradeoffs, and operational realities shaping modern biologics manufacturing. Bioprocess Online’s Tyler Menichiello...
In this session, leading CDMO experts will break down the key decisions across host cell selection, vector design, and clone screening strategies, and explain how those choices impact expression, scalability, and long-term manufacturability. These presentations will highlight how different CDMO approaches can reduce downstream risk or introduce it, as programs move from early development into...
What You’ll Learn: Gain insights into how renewed leasing activity, selective capital and improving absorption are reshaping demand, investment, and development decisions across the Bay Area life sciences market. Learn how owners, developers, and operators are rethinking space utilization, right sizing portfolios, and repositioning existing assets to meet today’s tenant expectations. Examine why South San...
Clinical trials sit at a unique intersection of science, patients, and clinical care, and for decades, the “gold standard” has prioritized the rigor of the data, often at the expense of the patients providing it. This gap between rigid protocol requirements and the realities of patients' lives is a primary driver of participant hesitancy and...
Join us for this digital event designed for pharmaceutical and biopharmaceutical companies seeking reliable CDMO partnerships to accelerate their microbial programs from development through commercial manufacturing. By attending this digital event, you will learn how these capabilities come together to support efficient development, smooth scale-up, and consistent production. The presentations will also provide insight into...
In this Capabilities Update, CDMOs will share how they support ADC programs from early development through clinical and commercial manufacturing. By attending this digital event, you will gain insight into the technical expertise, scalability, and regulatory considerations required to advance ADCs efficiently. The presentations will also highlight key considerations when evaluating CDMO partners, including experience...
